Posted by Michael Wonder on 10 Jun 2021
Adamis provides update on Zimhi
9 June 2021 - FDA deems new drug application for Zimhi complete and establishes a target action date of 12 November 2021.
Adamis Pharmaceuticals today announced that the U.S. FDA has accepted for review the Company’s resubmitted new drug application for Zimhi, which is its higher naloxone injection product candidate for the treatment of opioid overdose.
